| <p>Venmax Drugs & Pharmaceuticals Limited informed the BSE Limited that there was no deviation or variation in the use of Rs 20.05 crore raised through the issue of fully convertible equity warrants on a preferential basis, with Rs 18.49 crore already received as of September 30, 2026, according to a regulatory filing on November 12, 2026. The company stated that Rs 8.44 crore was utilized for working capital and Rs 10.05 crore for general corporate purposes and business acquisition until that date.</p> |